Point Therapeutics Inc is categorized under Commercial Biotechnical Research in Boston, MA and active since 1996.
Point Therapeutics Inc was established in 1996, and today employs 1 to 4, earning $500.000 to $999.999 per year. This is a Commercial Biotechnical Research business, which does work in the B2B market, and is classified as a Commercial Biotechnical Research, under code number 541711 by the NAICS.
If you are seeking more information, feel free to contact Donald Kiepert at the company’s single location by writing to 75 Kneeland St Floor 10, Boston, Massachusetts MA 02111 or by phoning (617) 636-0680. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Point Therapeutics Inc |
| Contact Person: | Donald Kiepert |
| Address: | 75 Kneeland St Floor 10, Boston, Massachusetts 02111 |
| Phone Number: | (617) 636-0680 |
| Annual Revenue (USD): | $500.000 to $999.999 |
| Founded: | 1996 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Biotechnical Research |
| SIC Code: | 8731 |
| NAICS Code: | 541711 |
| Share This Business: |
Point Therapeutics Inc was started in 1996 to provide professional Commercial Biotechnical Research under the SIC code 8731 and NAICS code 541711. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $500.000 to $999.999 per annum.
Feel free to contact Donald Kiepert for inquiries that concern Point Therapeutics Inc by calling the company number (617) 636-0680, as your correspondence is most welcome. Additionally, the physical location of the single location of Point Therapeutics Inc can be found at the coordinates as well as the street address 75 Kneeland St Floor 10 in Boston, Massachusetts 02111.
For its online presence, you may visit Point Therapeutics Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.